Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.51    -0.09 (-5.62%)
Bid:
1.51
Ask:
2.06
Spread: 0.55 (36.424%)
Market Cap: £5.30m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Holding(s) in Company

30 Dec 2016 11:42

RNS Number : 0878T
Proteome Sciences PLC
30 December 2016
 

TR-1:NOTIFICATION OFMAJOR INTERESTIN SHARESi

1. Identity of the issuer or the underlying issuer

of existing shares to which voting rights are PROTEOME SCIENCES PLC

attached: ii

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

YES

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

3. Full name of person(s) subject to the VULPES LIFE SCIENCES FUND

notification obligation: iii VULPES TESTUDO FUND

 

4. Full name of shareholder(s)

(if different from 3.):iv

5. Date of the transaction and date on

which the threshold is crossed or 28 DECEMBER 2016

reached: v

6. Date on which issuer notified: 29 DECEMBER 2016

7. Threshold(s) that is/are crossed or

reached: vi, vii 18%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of

shares

 

if possible using the ISIN CODE

Situation previous

to the triggering transaction

Resulting situation after the triggering transaction

Number

of Shares

Number

of Voting Rights

Number

of shares

Number of voting

rights

% of  voting rights

x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0003104196

 

 

52,973,125

 

 

52,973,125

 

 

53,238,125

 

 

53,238,125

 

18.09%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

xv, xvi

Resulting situation after the triggering transaction

Type of financial

instrument

Exercise

price

Expiration date xvii

Exercise/

Conversion period xviii

Number of voting rights

instrument refers to

% of voting rights xix, xx

Nomin al

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

53,238,125

18.09%

 

 

 

 

 

  Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

 

 

13. Additional information:

 

executive.pa@proteomics.com

14. Contact name:

 

Victoria Birse

15. Contact telephone number:

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLWGGGPPUPQGGU
Date   Source Headline
1st Jun 20267:00 amRNSDirectorate Changes
14th May 202612:55 pmRNSResult of AGM
14th May 202612:00 pmRNSAnnual General Meeting Statement
15th Apr 20267:00 amRNSFinal results for the year ended 31 December 2025
4th Feb 202611:08 amRNSHolding(s) in Company
3rd Feb 202612:43 pmRNSHolding(s) in Company
28th Jan 20263:31 pmRNSResult of Oversubscribed Retail Offer
26th Jan 20267:05 amRNSRetail Offer to raise up to £60,000
26th Jan 20267:00 amRNS£840,000 Fundraise and Retail Offer
6th Jan 20267:00 amRNSTwo Further Substantial Contracts for PRM
8th Dec 20257:00 amRNSSubstantial contract for Proteome Sciences
25th Nov 20257:00 amRNSAppointment of Nominated Adviser and Broker
25th Sep 20257:00 amRNSInterim Results
16th May 20251:17 pmRNSResult of AGM
16th May 202512:00 pmRNSAGM Statement
10th Apr 20257:00 amRNSFinal Results
4th Apr 20251:00 pmRNSNotice of Results and Investor Presentation
21st Feb 20257:00 amRNSContract Win
23rd Dec 20247:08 amRNSLoan Facility, Trading Update & Directorate Change
13th Sep 20247:00 amRNSInterim Results and Directorate Change
16th May 20241:10 pmRNSResult of AGM
16th May 20247:00 amRNSAGM Statement
26th Apr 20247:00 amRNSContract Win
10th Apr 20247:00 amRNSFinal Results
2nd Jan 20247:00 amRNSCompletion of new facility in San Diego
30th Nov 20237:00 amRNSTrading Update
2nd Oct 20237:00 amRNSLaunch of Single Cell Proteomics Services
30th Aug 20232:14 pmRNSInvestor Presentation
25th Aug 20237:00 amRNSInterim Results
1st Jun 20239:43 amRNSRepayment of Loan
17th May 20231:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
12th May 20237:00 amRNSExpansion into the US
14th Apr 202310:45 amRNSDirector/PDMR Shareholding
6th Apr 202311:34 amRNSDirector/PDMR Shareholding
6th Apr 202310:30 amRNSInvestor Presentation
4th Apr 20237:00 amRNSFinal Results
29th Mar 20237:00 amRNSNotice of Results
6th Mar 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:00 amRNSTrading Update
5th Jan 20237:00 amRNSMilestone Payment for TMT®/TMTpro™ Sales
1st Dec 20224:38 pmRNSGrant of Options and PDMR/director shareholdings
12th Oct 20227:00 amRNSGrant of Options and PDMR/director shareholdings
4th Oct 20227:00 amRNSChange of Auditor
20th Sep 20224:40 pmRNSSecond Price Monitoring Extn
20th Sep 20224:35 pmRNSPrice Monitoring Extension
18th Aug 20227:00 amRNSAppointment of Chief Financial Officer
11th Aug 20227:00 amRNSInvestor Presentation
4th Aug 20227:00 amRNSInterim Results
3rd Aug 20227:00 amRNSMilestone towards Single Cell Proteomics services

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.